COCEFEN 200

DESCRIPTION

A yellowish to brown-yellowoily suspension, with a slight odor of its components.

COMPOSITION

PHARMACOLOGICAL PROPERTIES

ATCvet Code: QJ01Antibacterials for system use. QJ01DD99 Ceftiofur, combinations.

Ceftiofur is an antibiotic ofthe cephalosporin type (third generation). It is active against bothgram-positive and gram-negative bacteria including beta-lactamase-producingstrains and some anaerobic bacteria: Escherichia coli, Pasteurella haemolytica,Pasteurella multocida, Haemophilus somnus, Actinobacillus pleuropneumoniae,Haemophilus parasuis, Salmonella cholerasuis, Streptococcus suis, Streptococcuszooepidemicus, Pasteurella spp, Staphylococcu0073 spp., Actynomyces pyogenes, Salmonellatyphimurium, Streptococcus agalactiae, S. dysgalactiae, S. bovis, Klebsiellaspp., Citrobacter spp., Enterobacter spp., Bacillus spp., Proteusspp., Fusobacterium necrophorum і Porphiromonas assacharolytica(Bacteroides melaninogenicus). The mode of action of the antibioticis inhibiting the bacterial cell wall synthesis.

Ketoprofen is a non-steroidalanti-inflammatory drug (NSAID) of the propionic acid class. Ketoprofen exertsthree main pharmacological effects which are common to all NSAIDs: antiinflammatory,analgesic and antipyretic. The primary mechanism of action is inhibition ofprostaglandin synthesis through interference with the cyclo-oxygenase pathwayof arachidonic acid metabolism. Also, ketoprofen has been shown to inhibitlipooxygenase, to have an anti-bradykinin activity, to stabilize lysosomalmembranes, and to cause a significant inhibition of neutrophil activity.Ketoprofen is a double inhibitor of inflammation through blocking the pathwaysof action of cycloxygenase and lipoxygenase thereby preventing prostaglandinsand leukotrienes from being produced.

Ketoprofen is an analgeticwhich exerts effect on the central nervous system and the peripheral nervoussystem. Its action is to inhibit directly the action of bradykinin, a vasodilatatorand pain mediator.

Following parenteraladministration, ceftiofur is absorbed quickly from the injection site andpenetrates all of the animal tissues. Its maximum plasma concentration isobserved in one hour after administration; its plasma concentration is kept atthe therapeutic level for up to 24 hours depending of the animal species.Ceftiofur metabolizes readily within the body to form desfuroylceftiofur whichpossesses activity equivalent to that of ceftiofur with respect to bacteria.This active metabolite binds reversibly to plasma proteins and is accumulated inthe nidus of infection; its activity does not fall at the presence ofnecrotized tissues.

The antibiotic is excretedmostly with the urine and feces.

Ketoprofen is absorbedquickly. Over 98% bind to plasma proteins and are accumulated in inflamedtissues. In cattle, the peak plasma levels (8.025 μg/mL ± 1.9 μg/mL) are reached for lessthan one hour after intramuscular administration. Significant concentrations ofketoprofen have been reported to be found in the synovial fluid, and its levelthere in higher than that in the plasma and its elimination half-life is 2 to 3times that in the plasma. Ketoprofen metabolizes in the liver intoinsignificant biologically active metabolites and 90% are excreted with theurine in the form of glucuronide compounds.

INDICATIONS

Treatment of cattle sufferingfrom necrobacteriosis and endometritis, as well as from respiratory diseasescaused by microorganisms sensitive to ceftiofur.

DOSAGE AND ADMINISTRATION

Administer the drug once dailyat a dose rate of 1 mL per 50 kg b.w. (1 mg of ceftiofur and 3 mg of ketoprofenper 1 kg b.w.) for 3 to 5 days for respiratory diseases, for 3 days fornecrobacteriosis, and for 5 days for endometritis.

Before administration, shakethe vial containing the drug and heat it up to 36 °С.

CONTRAINDICATIONS

WITHDRAWAL PERIOD

HOW SUPPLIED

Neutral glass vials of 10-mL,20-mL, 50-mL; 100-mL; and 200-mL, closed by a rubber stopper and sealed with analuminum cover. Secondary package: cartons.

STORAGE

Shelf life